secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001104659-26-044906
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva reports positive VIRAGE Phase 2b data for VCN-01 in pancreatic cancer at AACR 2026
--------------------------------------------------------------------------------

- VCN-01 + gemcitabine/nab-paclitaxel improved OS and PFS vs GnP alone in metastatic pancreatic cancer patients.
- Later-emerging, higher magnitude, more durable responses observed; benefit maintained across subgroups including liver metastases.
- Patients receiving a second VCN-01 dose showed greater OS and PFS benefit.
- CEO reported alignment with FDA and EMA on proposed pivotal Phase 3 trial; planning study of more frequent VCN-01 dosing.
- Data presented at AACR 2026 (poster CT162) on April 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465926044906/0001104659-26-044906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465926044906/tm2612012d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer